A U.K. pension group recommended that members vote against drugmaker AstraZeneca Plc’s remuneration policy to protest a “golden hello” payment and planned incentives for Chief Executive Officer Pascal Soriot.
AstraZeneca Plc will cut about 1,600 jobs as it overhauls research and development, leading to $1.4 billion in costs as new Chief Executive Officer Pascal Soriot tries to revive the U.K.’s second-biggest drugmaker.
David Brennan couldn’t sit still. During a meal of beef and potatoes at AstraZeneca Plc’s drug research center near Stockholm in October, Brennan, the company’s chief executive officer, grilled six drug-development managers over a concern raised by a laboratory scientist.
AstraZeneca Plc Chief Executive Officer David Brennan will retire from his post, ending a six- year tenure after repeated failures in drug development left investors skeptical of the company’s earnings prospects.
AstraZeneca Plc suspended share buybacks as the board and new Chief Executive Officer Pascal Soriot review strategy at the U.K. drugmaker, prompting renewed speculation that the company will embark on larger takeovers.
AstraZeneca Plc , the U.K.’s second- largest drugmaker, is scaling up its up its operations in South Africa, where sales are growing faster than in more established markets, Chief Executive Officer David Brennan said.